Search results
Results from the WOW.Com Content Network
An article published by the journal Nature on 6 July 2021 cited data released by the United Arab Emirates on some 81,000 individuals who had received Sputnik V, according to which the vaccine demonstrated an efficacy of 97.8% in preventing symptomatic COVID-19, and 100% efficacy in preventing severe complications.
Russia was quick to develop its two-dose Sputnik V vaccine last year and has also deployed a one-shot Sputnik Light vaccine, both of which have it says demonstrated high efficacy in trials, but ...
This page is a list of Russian drugs, or drugs that were developed in Russia, the former Soviet Union, and/or post-Soviet countries.. Many Russian drugs are indicated for enhancing physical, mental, and/or cognitive performance, including drugs described as nootropics or cognitive enhancers, drugs combatting fatigue, so-called adaptogens or actoprotectors, and others.
In addition, vaccine developers have been criticized for aggressively advertising their vaccine efficacy prior to the completion of phase III clinical trial. The most substantial criticism came from Dr. Konstantin Chumakov, who currently serves as the associate director for Research at the FDA Office of Vaccines Research and Review.
Vaccines from AstraZeneca , Russia's Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual ...
He also defended the vaccine's early registration for public use, saying it was the most ethical approach. Russia plans to test in several countries, including Belarus, Brazil and India.
The head of the Russian Direct Investment Fund (RDIF) stated that 20 countries had requested in total 1 billion doses of the vaccine, nicknamed Sputnik V. [11] On August 20 registration was called "conditional" with final registration depends on results of Phase 3 trial, [12] such registration is limited and allowed by Decree 441 for medicines ...
English: Sputnik V efficacy for different conditions. Data from: Logunov D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.